Furthermore, tissue arrays collected from 151 glioma cases revealed that the group with higher expression of ITPKB had poorer overall survival (median OS: 86 vs. 99 months, p < 0.001) and PFS (median PFS: 85 vs. 99 months, p < 0.001) than the lower expression group (Fig. 1k, l). Here, ITPKB is linked to central nervous system cancer.